CN107449925A - A kind of buffer solution and detection method for suppressing analyte detection for blood coagulation factor VIII - Google Patents
A kind of buffer solution and detection method for suppressing analyte detection for blood coagulation factor VIII Download PDFInfo
- Publication number
- CN107449925A CN107449925A CN201710857119.4A CN201710857119A CN107449925A CN 107449925 A CN107449925 A CN 107449925A CN 201710857119 A CN201710857119 A CN 201710857119A CN 107449925 A CN107449925 A CN 107449925A
- Authority
- CN
- China
- Prior art keywords
- factor viii
- blood coagulation
- coagulation factor
- buffer solution
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
Abstract
The invention discloses a kind of buffer solution and detection method for suppressing analyte detection for blood coagulation factor VIII, it is related to clinical detection of blood coagulation formulation art.Buffer solution disclosed by the invention, based on every L, it contains：2.62 2.82g imidazoles, 4.53 4.83g NaCl, 8.1 8.7g BSA, 0.017 0.023ml polysorbas20s, 6.3 6.7g NaN3And 14.78 14.98mmol HCl.The buffer solution can be used for diluting blood sample in blood coagulation factor VIII or blood coagulation factor VIII mortifier detection process, and it just has preferable buffer capacity, can improve the stability of testing result.
Description
Technical field
The present invention relates to clinical detection of blood coagulation formulation art, is used for blood coagulation factor VIII in particular to one kind and suppresses
The buffer solution and detection method of analyte detection.
Background technology
Hemophilia A is the hemorrhagic disease that a kind of genetic, blood coagulation factor VIII lacks, and current treatment means are main
It is Factor IX replacement therapy, but chronic infusion Factor IX can produce mortifier in inductor, data shows blood friend
After sick A patient's infusion of factors VIII treatments, about 15%-30% patient can produce mortifier, and the generation of mortifier is hemophilia
The complication of the most serious occurred in therapeutic process, how to reduce the generation of hemophilia mortifier is current Treatment of Hemophilia neck
The great difficult problem that domain faces.At present because infusion clotting factor is the only effective therapeutic modality of haemophiliac, pass through monitoring
The horizontal direction of medication usage of mortifier is critically important in Treatment of Hemophilia.Hemophilia alliance of the world (World Federation of
Hemophilia, WFH) in issue in 2012《Hemophilia administration guide》In clearly propose that haemophiliac carries out replacement and controlled
Treat, should all carry out suppression analyte detection before operation and therapeutic evaluation.
But due to carrying out, the reagent type that uses of blood coagulation factor VIII mortifier detection project is various, operation sequence is multiple
Miscellaneous, working specification and quality control are difficult to hold, and the project that domestic development suppresses analyte detection at present is seldom.
The content of the invention
It is an object of the invention to provide a kind of buffer solution for suppressing analyte detection for blood coagulation factor VIII, and it has preferable
Buffer capacity, improve the stability of testing result.
Another object of the present invention is to provide the application of above-mentioned buffer solution.
Another object of the present invention is to provide a kind of kit for detecting blood coagulation factor VIII mortifier.
Another object of the present invention is to provide a kind of method for detecting blood coagulation factor VIII.
Another object of the present invention is to provide the method for detection blood coagulation factor VIII mortifier.
What the present invention was realized in：
A kind of buffer solution for suppressing analyte detection for blood coagulation factor VIII, based on every L, it contains：2.62-2.82g imidazoles,
4.53-4.83g NaCl, 8.1-8.7g BSA, 0.017-0.023ml Tween-20s, 6.3-6.7g NaN3And 14.78-
14.98mmol HCl。
The above-mentioned blood coagulation factor VIII that is used for suppresses the buffer solution of analyte detection in detection blood coagulation factor VIII or clotting factor
Application in VIII mortifiers.
A kind of kit for detecting blood coagulation factor VIII mortifier, it, which contains, above-mentioned is used for blood coagulation factor VIII mortifier
The buffer solution of detection.
A kind of method for detecting blood coagulation factor VIII, it includes：Suppress analyte detection with the above-mentioned blood coagulation factor VIII that is used for
Buffer solution diluting plasma.
A kind of method for detecting blood coagulation factor VIII mortifier, it includes：Suppressed with the above-mentioned blood coagulation factor VIII that is used for
The buffer solution of analyte detection carries out doubling dilution to test plasma, obtains more parts of test plasma dilutions.
The invention has the advantages that：
Suppress the buffer solution of analyte detection provided by the present invention for blood coagulation factor VIII, based on every L, it contains：2.62-
2.82g imidazoles, 4.53-4.83g NaCl, 8.1-8.7g BSA, 0.017-0.023ml Tween-20s, 6.3-6.7g NaN3With
And 14.78-14.98mmol HCl.The buffer solution can be used for suppressing analyte detection mistake in blood coagulation factor VIII or blood coagulation factor VIII
Journey dilutes to blood sample, and it just has preferable buffer capacity, can improve the stability of testing result.
Brief description of the drawings
In order to illustrate the technical solution of the embodiments of the present invention more clearly, below by embodiment it is required use it is attached
Figure is briefly described, it will be appreciated that the following drawings illustrate only certain embodiments of the present invention, therefore be not construed as pair
The restriction of scope, for those of ordinary skill in the art, on the premise of not paying creative work, can also be according to this
A little accompanying drawings obtain other related accompanying drawings.
Canonical plottings of the Fig. 1 between factor VIII activity provided in an embodiment of the present invention and ATPP times；
Fig. 2 is that remaining factor VIII activity provided in an embodiment of the present invention and blood coagulation factor VIII mortifier are horizontal
Between relation.
Embodiment
, below will be in the embodiment of the present invention to make the purpose, technical scheme and advantage of the embodiment of the present invention clearer
Technical scheme be clearly and completely described.Unreceipted actual conditions person, builds according to normal condition or manufacturer in embodiment
The condition of view is carried out.Agents useful for same or the unreceipted production firm person of instrument, it is the conventional production that can be obtained by commercially available purchase
Product.
Below to a kind of buffer solution and detection side for suppressing analyte detection for blood coagulation factor VIII of the embodiment of the present invention
Method is specifically described.
On the one hand, the buffer solution provided in an embodiment of the present invention for suppressing analyte detection for blood coagulation factor VIII, based on every L,
It contains：2.62-2.82g imidazoles, 4.53-4.83g NaCl, 8.1-8.7g BSA, 0.017-0.023ml Tween-20s, 6.3-
6.7g NaN3And 14.78-14.98mmol HCl.
Further, in certain embodiments of the present invention, based on every L, the buffer solution contains：2.67-2.77g miaow
Azoles, 4.58-4.78g NaCl, 8.2-8.6g BSA, 0.019-0.021ml Tween-20s, 6.4-6.6g NaN3And 14.83-
14.93mmol HCl。
Further, in certain embodiments of the present invention, based on every L, the buffer solution contains：2.72g imidazoles,
4.68g NaCl, 8.4g BSA, 0.02ml Tween-20s, 6.5g NaN3And 14.88mmol HCl.
Further, in certain embodiments of the present invention, the pH of the buffer solution is 7.1-7.4.
Further, in certain embodiments of the present invention, the pH of the buffer solution is 7.3.
It is provided in an embodiment of the present invention for blood coagulation factor VIII suppress analyte detection buffer solution, by formula again
Design, makes it have preferable buffer capacity, available in blood coagulation factor VIII or blood coagulation factor VIII mortifier detection process
In blood sample is diluted, improve the stability of testing result, and its cost has wide well below existing buffer solution
Application prospect.
On the other hand, the embodiments of the invention provide the above-mentioned buffer solution for suppressing analyte detection for blood coagulation factor VIII to examine
The application surveyed in blood coagulation factor VIII or blood coagulation factor VIII mortifier.
Buffer solution provided in an embodiment of the present invention is used to detect blood coagulation factor VIII or blood coagulation factor VIII mortifier, can
To improve the stability of testing result, contribute to the standard criterion to clotting factor mortifier test experience and quality control.
On the other hand, the embodiment of the present invention additionally provides a kind of kit for detecting blood coagulation factor VIII mortifier, and it contains
There is the above-mentioned buffer solution for being used for blood coagulation factor VIII and suppressing analyte detection.
On the other hand, the embodiment of the present invention additionally provides a kind of method for detecting blood coagulation factor VIII, and it includes：With above-mentioned
The buffer solution diluting plasma for being used for blood coagulation factor VIII or blood coagulation factor VIII and suppressing analyte detection.
Further, in certain embodiments of the present invention, the volume ratio of the buffer solution and the blood plasma is (0.8-
1.2):(4.7-5.2)。
Further, in certain embodiments of the present invention, the volume ratio of the buffer solution and the blood plasma is 1:5.
Another further aspect, the embodiment of the present invention additionally provide a kind of method for detecting blood coagulation factor VIII mortifier, and it includes：
Be used to blood coagulation factor VIII and suppress the buffer solution of analyte detection carrying out doubling dilution to test plasma with above-mentioned, obtain more parts it is to be measured
Plasma extender.
Further, in certain embodiments of the present invention, methods described also includes：Detect every part of test plasma
Remnants (relative surplus) factor VIII activity of dilution.
Further, in certain embodiments of the present invention, remaining blood coagulation factor VIII activity is selected in 30%-
The extension rate of 60% test plasma dilution is used to calculate blood coagulation factor VIII mortifier.
Further, in certain embodiments of the present invention, remaining (relative surplus) factor VIII activity is selected
It is used to calculate blood coagulation factor VIII mortifier in the extension rate of 50% test plasma dilution.
The method of detection blood coagulation factor VIII mortifier provided by the invention can be that haemophiliac and clinician carry
For more comprehensively accurate clinical therapeutic efficacy evaluation index, help patient to adjust treatment method, effectively reduce hemophilia suppression
The generation of thing.
The feature and performance of the present invention are described in further detail with reference to embodiments.
Embodiment 1
The buffer solution for being used for blood coagulation factor VIII and suppressing analyte detection that the present embodiment provides, based on every L, the buffer solution contains for it
Have：2.72g imidazoles, 4.68g NaCl, 8.4g BSA, 0.02ml Tween-20s, 6.5g NaN3And 14.88mmol HCl.
The preparation method of above-mentioned buffer solution is present embodiments provided, it is as follows：
1. weigh 2.72g imidazoles, 4.68g NaCl, 8.4g BSA, 0.02ml Tween-20s and 6.5g NaN3It is placed in appearance
In measuring bottle, 500ml distilled water, stirring and dissolving are added；
2. adding 148.8ml 0.1M hydrochloric acid, it is 7.3 that pH is adjusted after mixing；
3. being settled to 1L with distilled water, adjustment pH is 7.3.
The buffer solution for being used for blood coagulation factor VIII and suppressing analyte detection that the present embodiment provides, it has preferable buffer capacity
Power, blood sample is diluted available in blood coagulation factor VIII or blood coagulation factor VIII mortifier detection process, improve detection
As a result stability.
Embodiment 2
The method for the detection blood coagulation factor VIII that the present embodiment provides, it comprises the following steps：
1 sample collection
20 healthy normal person's cubital venous blood samplings (sample number consecutively is 1,2,3 ..., 20).On being pricked before blood sampling starts
Tourniquet, use 109mmlol/L sodium citrate anti-freezing (blood：Sodium citrate=9:1) vacuum blood collection tube collection blood sample 3ml, note
It is intended to blood and is evacuated to after anti-coagulants pipe, it is necessary to gently turn upside down five times mix.
The step is optional step.
2 separated plasmas
The blood sample of fresh collection separated plasma in 1 hour, heparin tube is placed in centrifuge, under 1600g centrifugal force
Blood plasma, is transferred in 1.5ml centrifuge tube, blood plasma can be deposited at room temperature by centrifugation 15 minutes using 200 μ l micropipettor
Put 3 hours, -20 DEG C can deposit 2 weeks.
The step is optional step.
3. using factor VIII activity in freezing method detection blood plasma
3.1 buffer solutions provided with embodiment 1 press 1:5 dilution proportion plasma samples, recover to 15-25 DEG C, 37 DEG C of room temperature
Water bath warm bath；
3.2 warm bath 0.025M calcium chloride solutions, it is positioned over warm bath 3 minutes in 37 DEG C of water baths；
3.3 sequentially add weary blood coagulation factor VIII blood plasma 100ul, diluting plasma sample 100 μ l and APTT in cuvette
The μ l of reagent 100, mix, be placed in warm bath 3 minutes in 37 DEG C of water baths, gently shake；
3.4 add calcium chloride (CaCl2) 100 μ l of solution, while start the timer on stopwatch or coaglation analyzer,
The start recording clotting time (i.e. APTT times)；
3.5 read the activity of blood coagulation factor VIII from reference curve, are represented with %.
Wherein, reference curve be using blood coagulation factor VIII calibration object (6 concentration gradients are 89% respectively, 44.5%,
11.125%th, 5.563% the APTT times, 1.113%, 0.001%) made and the curve of factor VIII activity relation.
Factor VIII activity can be calculated according to the APTT times by sample during detection.Reference curve is that double Log of point-to-point intend
Close curve (be a line segment (1 line segment represents 1 equation) between two adjacent points, Log (Y)=a × Log (X)+b, Y
The APTT times (second) are represented, X represents the activity (%) of blood coagulation factor VIII), as shown in figure 1, abscissa is blood coagulation factor VIII
Activity (%), ordinate is APTT times (second).
3.6 result
The factor VIII activity testing result of 20 normal healthy peoples, is shown in Table 1.
The healthy normal person VIII factors check results of 1 20, table
| Sample number | 1 | 2 | 3 | 4 | 5 | 6 |
| Factor VIII activity/% | 128.68 | 114.89 | 101.41 | 94.74 | 104.24 | 123.29 |
| Sample number | 7 | 8 | 9 | 10 | 11 | 12 |
| Factor VIII activity/% | 90.99 | 125.06 | 100.04 | 116.51 | 89.78 | 130.54 |
| Sample number | 13 | 14 | 15 | 16 | 17 | 18 |
| Factor VIII activity/% | 151.3 | 107.16 | 84.36 | 132.43 | 79.69 | 138.3 |
| Sample number | 19 | 20 | ||||
| Factor VIII activity/% | 92.22 | 110.17 |
Embodiment 3
The method for the detection blood coagulation factor VIII mortifier that the present embodiment provides, concrete operations are as follows：
The 1 remaining factor VIII activity of detection
1.1 using the imidazole buffer that embodiment 1 provides as plasma extender, by one because of length in plastic test tube
Phase is using recombinant blood coagulation factor VIII drug therapies and has produced haemophiliac's blood plasma of blood coagulation factor VIII antibody (through inspection
Survey, the blood coagulation factor VIII of patients blood plasma activity for 0.001%) carry out doubling dilution (1 times, 5 times, 10 times, 20 times, 40
Again, 80 times, 160 times, 320 times), the Plasma volumes of each multiple are 0.2ml.
The weary blood coagulation factor VIII blood plasma of 0.2ml is sucked another plastic test tube by 1.2, is compareed as standard plasma.
1.3 by the test plasma after the normal pooled plasma addition standard pipes of 0.2ml and dilution.Now all blood to be measured
The horizontal factor VIII activity of slurry is about 50% (note：The blood coagulation factor VIII of normal pooled plasma is 100%, patient
Blood plasma and each diluting plasma are 0%, 50%) factor VIII activity after mixed in equal amounts is about.Incubation is examined after terminating
During survey, the factor VIII activity of standard plasma is considered as 100%.
1.4 cover all test tubes, well mixed and be positioned in 37 DEG C of water baths and be incubated 2 hours.
The 1.5 step 3.1-3.5 pressed in embodiment 2 carry out blood coagulation to the test plasma after all incubations and standard plasma
Factor VIU activity detects, and testing result is designated as m, the clotting factor of standard plasma as remaining blood coagulation factor VIII activity
VIII activity assays are designated as w.
1.6 using the factor VIII activity of standard plasma as 100%, and the remnants for calculating every part of test plasma are (relative
It is remaining) factor VIII activity, it is calculated as follows：
Remaining (relative surplus) factor VIII activity=(m ÷ w) × 100%；
Wherein, m represents the remaining factor VIII activity of test plasma, and w represents the actually detected of standard plasma and coagulated
Blood factor VIII activity.It the results are shown in Table 2.
2 calculate blood coagulation factor VIII mortifier
According to remnants (relative surplus) blood coagulation factor VIII activity level of the every part of test plasma calculated, select residual
(corresponding extension rate is 160 to dilution factor of remaining (relative surplus) factor VIII activity close to 50% in the present embodiment
Times), and be multiplied by extension rate and be corrected, obtain the blood coagulation factor VIII mortifier level of test plasma, blood coagulation factor VIII
Mortifier level calculation formula：Mortifier level (Y), remaining (relative surplus) factor VIII activity (X%), Y=(2-
lgX)÷0.30103。
, can remaining (relative surplus) blood coagulation factor VIII activity %- mortifier units according to the definition of mortifier unit
Standard curve is drawn on double logarithmic curve (see Fig. 2, in figure：1 Bethesda unit definition is：37 DEG C are incubated 2 hours, in
With the amount of 50% mortifier of a unit blood coagulation factor VIII of exogenous addition, remaining FVIII represents remaining (relatively surplus
It is remaining) blood coagulation factor VIII), Fig. 2 references are hemophilia alliance of the world (WFH) the hemophilia laboratory diagnosis issued in 2010
Handbook.
It the results are shown in Table 2.
Remaining factor VIII activity and blood coagulation factor VIII the mortifier level after being incubated 2 hours of table 2
It can be seen from table 2, the blood coagulation factor VIII mortifier level in haemophiliac's blood plasma in the present embodiment is
173.83BU/ml。
It should be noted that in other examples, relative surplus factor VIII activity may be selected in 30-
Test plasma extension rate in the range of 60% is used for the calculating of mortifier, need to only calculate the mortifier of every part of dilution test plasma
Testing result, average.
Embodiment 4
It is used for the buffer solution buffer capacity checking that blood coagulation factor VIII suppresses analyte detection to the detection that embodiment 1 provides
The method of the detection blood coagulation factor VIII provided using embodiment 2, with different buffer solutions, (embodiment 1 provides
Buffer solution, weary VIII factors blood plasma, two kinds of different diluted plasma buffer solutions of blood coagulation commercially), different
Time point detects the factor VIII activity with a blood sample.
Specially：The blood coagulation of normal pooled plasma is first detected because VIII is active (normal pooled plasma before incubation), then will
Four kinds of buffer solutions are mixed with 200 μ l normal pooled plasma grade ratio respectively, and factor VIII activity level (detection altogether is detected after mixing
2 times, detection the 1st time, the 2nd time before being respectively incubated), then 37 DEG C of water baths are incubated 2 hours, detect remaining clotting factor afterwards
VIII activity (after 37 DEG C are incubated 2 hours).Blood coagulation factor VIII factor active reduces the slow of the small buffer solution of amplitude before and after incubation
It is preferable to rush ability.As a result it is as shown in table 3 below.
Table 3
In table：Buffer A, C are the widely used blood coagulation diluted plasma buffer solution of in the market, and buffer B is improved
Imidazole buffer (embodiment 1 provide buffer solution), buffer solution D be weary blood coagulation factor VIII blood plasma (blood plasma product, cost compared with
Height, it is not suitable for use in plasma extender use).
Two Testing index in table 3 are related, and factor VIII activity can be by the APTT times according to reference to bent
Line calculates.Blood coagulation factor VIII is a kind functional biological activity protein, the extension that coagulation function activity can over time and
Gradually reduce, the change of some indexs (such as acid-base value, protein content, ionic strength etc.) of plasma extender can all cause to coagulate
The decline of blood factor VIII activity, such as weary blood coagulation factor VIII blood plasma contain the various blood constituents except blood coagulation factor VIII,
Therefore factor VIII activity level declines seldom after being incubated 2 hours.Blood coagulation factor VIII suppress analyte detection be patient's blood plasma and
After 37 DEG C of normal plasma mixing is incubated 2 hours, cause the degree of normal plasma factor VIII activity reduction, reduction degree is got over
Greatly, then blood coagulation factor VIII mortifier level is higher, and to reduce, this because of non-empirical factor, (buffer solution causes clotting factor
VIII activity decreases) caused by factor VIII activity decline influence to experimental result, buffer solution maintains clotting factor
Function activity stabilized VIII is critically important.It is more suitable to reduce the less buffer solution of amplitude for blood coagulation factor VIII factor active before and after incubation
Close and carry out blood coagulation factor VIII suppression analyte detection.
As it can be seen from table 1 the buffer solution diluting plasma provided using weary blood coagulation factor VIII blood plasma and embodiment 1,
Factor VIII activity reduction amplitude is minimum before and after incubation, is 0.96% and 1.78% respectively, and it reduces amplitude and is far below it
His diluted plasma buffer solution.Thus illustrate, the buffer solution for suppressing analyte detection for blood coagulation factor VIII that embodiment 1 provides delays
It is preferable to rush ability, suitable in blood coagulation factor VIII or the use of blood coagulation factor VIII mortifier detection process, raising testing result
Stability simultaneously reduce cost (implement 1 provide buffer solution price be about 0.15 ten thousand yuan/liter, weary blood coagulation factor VIII blood plasma
Price is about 300,000 yuan/liter, and weary blood coagulation factor VIII blood plasma product, cost is higher, is not suitable for use in plasma extender use).
The preferred embodiments of the present invention are the foregoing is only, are not intended to limit the invention, for the skill of this area
For art personnel, the present invention can have various modifications and variations.Within the spirit and principles of the invention, that is made any repaiies
Change, equivalent substitution, improvement etc., should be included in the scope of the protection.
Claims (10)
1. a kind of buffer solution for suppressing analyte detection for blood coagulation factor VIII, it is characterised in that based on every L, it contains：2.62-
2.82g imidazoles, 4.53-4.83g NaCl, 8.1-8.7g BSA, 0.017-0.023ml Tween-20s, 6.3-6.7g NaN3And
14.78-14.98mmol HCl。
2. the buffer solution according to claim 1 for suppressing analyte detection for blood coagulation factor VIII, it is characterised in that by every L
Meter, the buffer solution contain：2.67-2.77g imidazoles, 4.58-4.78g NaCl, 8.2-8.6g BSA, 0.019-0.021ml are told
Temperature -20,6.4-6.6g NaN3And 14.83-14.93mmol HCl.
3. the buffer solution according to claim 1 for suppressing analyte detection for blood coagulation factor VIII, it is characterised in that described slow
The pH of fliud flushing is 7.1-7.4.
4. the blood coagulation factor VIII that is used for described in claim any one of 1-3 suppresses the buffer solution of analyte detection in detection clotting factor
Application in VIII or blood coagulation factor VIII mortifier.
5. a kind of kit for detecting blood coagulation factor VIII mortifier, it is characterised in that it contains any one of claim 1-3 institutes
The buffer solution for being used for blood coagulation factor VIII and suppressing analyte detection stated.
A kind of 6. method for detecting blood coagulation factor VIII, it is characterised in that it includes：Described in claim any one of 1-3
Suppress the buffer solution diluting plasma of analyte detection for blood coagulation factor VIII.
7. the method for detection blood coagulation factor VIII according to claim 6, it is characterised in that the buffer solution and the blood
The volume ratio of slurry is (0.8-1.2):(4.7-5.2).
A kind of 8. method for detecting blood coagulation factor VIII mortifier, it is characterised in that it includes：With any one of claim 1-3
The described buffer solution for being used for blood coagulation factor VIII suppression analyte detection carries out doubling dilution to test plasma, obtains more parts of blood to be measured
Starch dilution.
9. the method for detection blood coagulation factor VIII mortifier according to claim 8, it is characterised in that methods described is also wrapped
Include：Detect remnants (relative surplus) factor VIII activity of every part of test plasma dilution.
10. the method for detection blood coagulation factor VIII mortifier according to claim 9, it is characterised in that the remaining (phase of selection
To residue) factor VIII activity 30%-60% test plasma dilution extension rate be used for calculate clotting factor
VIII mortifiers are horizontal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710857119.4A CN107449925A (en) | 2017-09-22 | 2017-09-22 | A kind of buffer solution and detection method for suppressing analyte detection for blood coagulation factor VIII |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710857119.4A CN107449925A (en) | 2017-09-22 | 2017-09-22 | A kind of buffer solution and detection method for suppressing analyte detection for blood coagulation factor VIII |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107449925A true CN107449925A (en) | 2017-12-08 |
Family
ID=60497714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710857119.4A Pending CN107449925A (en) | 2017-09-22 | 2017-09-22 | A kind of buffer solution and detection method for suppressing analyte detection for blood coagulation factor VIII |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107449925A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5227304A (en) * | 1991-01-16 | 1993-07-13 | Sequoia Turner Corporation | Method for counting whole blood diluent and detergent reagent system |
| CN1265196A (en) * | 1997-08-01 | 2000-08-30 | 库尔特国际公司 | Blood diluent |
| WO2001087357A2 (en) * | 2000-05-17 | 2001-11-22 | The American National Red Cross | Gamma irradiation of protein-based pharmaceutical products |
| CN107108746A (en) * | 2014-09-26 | 2017-08-29 | 中外制药株式会社 | The antibody of the active material with the function of replacing coagulation factors VIII (FVIII) can be neutralized |
-
2017
- 2017-09-22 CN CN201710857119.4A patent/CN107449925A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5227304A (en) * | 1991-01-16 | 1993-07-13 | Sequoia Turner Corporation | Method for counting whole blood diluent and detergent reagent system |
| CN1265196A (en) * | 1997-08-01 | 2000-08-30 | 库尔特国际公司 | Blood diluent |
| WO2001087357A2 (en) * | 2000-05-17 | 2001-11-22 | The American National Red Cross | Gamma irradiation of protein-based pharmaceutical products |
| CN107108746A (en) * | 2014-09-26 | 2017-08-29 | 中外制药株式会社 | The antibody of the active material with the function of replacing coagulation factors VIII (FVIII) can be neutralized |
Non-Patent Citations (1)
| Title |
|---|
| WFH 实验室科学委员会: "《血友病和其它出血性疾病诊断 实验室手册 第二版》", 31 December 2010, 世界血友病联盟(WFH)出版 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peters et al. | COVID-19–related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids | |
| Dunlop et al. | Low dialysate sodium levels for chronic haemodialysis | |
| Mindikoglu et al. | Performance of chronic kidney disease epidemiology collaboration creatinine‐cystatin C equation for estimating kidney function in cirrhosis | |
| Claasen et al. | Direct observation of ligand binding to membrane proteins in living cells by a saturation transfer double difference (STDD) NMR spectroscopy method shows a significantly higher affinity of integrin αIIbβ3 in native platelets than in liposomes | |
| Hirose et al. | Prevalence and prognostic implications of malnutrition as defined by GLIM criteria in elderly patients with heart failure | |
| Alper et al. | Performance of estimated glomerular filtration rate prediction equations in preeclamptic patients | |
| Friedman et al. | Measuring the glomerular filtration rate in obese individuals without overt kidney disease | |
| JPH06510210A (en) | Blood loss monitoring method and device | |
| Murray et al. | Defining acidosis in postoperative cardiac patients using Stewart’s method of strong ion difference | |
| JP7125824B2 (en) | Methods for personalizing biomarker signals and medical procedures using same | |
| Yilmaz et al. | The relationship of fluid overload as assessed by bioelectrical impedance analysis with pulmonary arterial hypertension in hemodialysis patients | |
| Depner et al. | Imprecision of the hemodialysis dose when measured directly from urea removal | |
| Shin et al. | Phase angle as a marker for muscle health and quality of life in patients with chronic kidney disease | |
| Miyasato et al. | Associations between visceral obesity and renal impairment in health checkup participants: a retrospective cohort study | |
| CN107449925A (en) | A kind of buffer solution and detection method for suppressing analyte detection for blood coagulation factor VIII | |
| Flores et al. | Tissue plasminogen activator plasma levels as a potential diagnostic aid in acute pulmonary embolism | |
| Gorelik et al. | Renal functional recovery confounding the assessment of contrast nephropathy: propensity score analysis | |
| CN108133754B (en) | The forecasting system of bleeding risk after a kind of thrombolysis | |
| CN107942048A (en) | A kind of detection reagent, its preparation method and the application of D dimers | |
| Tonelli et al. | Access flow in arteriovenous accesses by optodilutional and ultrasound dilution methods | |
| Marano et al. | pCO2 reveals arteriovenous fistula recirculation in bicarbonate hemodialysis (RecirCO2lation test) | |
| Zhang et al. | Establishing reference intervals of aspartate aminotransferase-to-platelet ratio index for apparently healthy elderly | |
| Horak et al. | Measurements of serum urea nitrogen by conductivimetric urease assay | |
| Cartier et al. | Pseudohypobicarbonatemia in a patient presenting with suspected diabetic ketoacidosis | |
| Refaai et al. | Performance of the microINR point-of-care system: a multicenter clinical trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171208 |
|
| RJ01 | Rejection of invention patent application after publication |